Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Point Of Care Glucose Testing Market Size

ID: MRFR/HC/10743-HCR
132 Pages
Rahul Gotadki
April 2026

Point Of Care Glucose Testing Market Research Report: Size, Share, Trend Analysis By Product Type (Lancing Devices and Strips and Blood-Glucose Meter), By Applications (Type-1 Diabetes and Type-2 Diabetes), By End Users (Hospitals and Clinics, Home Care Settings, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Point Of Care Glucose Testing Market Infographic
Purchase Options

Point Of Care Glucose Testing Size

Point Of Care Glucose Testing Market Growth Projections and Opportunities

The market for Point of Care Glucose Testing (POCT) is driven by the rising pervasiveness of diabetes around the world, which requires helpful and speedy glucose testing arrangements. As the commonness of diabetes expands, there is a developing accentuation on the POCT to speedily and promptly evaluate blood glucose levels. Developments in glucose observing gadgets innovation, including CGM frameworks, handheld meters, and cell phone coordinated arrangements, are essentially affecting the POCT glucose testing market. These headways work on the exactness of glucose testing and improve the patient experience through the arrangement of cutting-edge data. In vitro diagnostics, including glucose testing gadgets, are significantly impacted by the administrative climate. Guaranteeing tests stick to thorough guidelines is critical for laying out certainty among medical services suppliers and patients, as it influences endorsement, commercialization, and clinical reception by advancing accuracy, trustworthiness, and wellbeing. Reception of POCT glucose testing is impacted by repayment strategies, financial variables, and medical services foundation in different districts; accordingly, market members should adjust to explicit hindrances. Continuous innovative work pushes the POCT glucose testing market, as demonstrative organizations give a variety of arrangements that display improved accuracy and ease of use, in this manner empowering development. Market development is moved by global associations among demonstrative associations, research foundations, and medical care associations. These coordinated efforts produce novel glucose detecting advances, upgrade testing calculations, and further develop network arrangements that are explicitly intended for diabetes the board. This collaboration facilitates the movement of POCT glucose checking. Glucose testing arrangements that focus on exactness, client accommodation, inconvenience decrease, and ease of use are acquiring portion of the overall industry. Ideal POCT glucose testing arrangements that stick to this worldview upgrade the experience of overseeing diabetes. The reception of POCT glucose testing is considerably affected by open mindfulness and instruction crusades, which engage people to oversee diabetes and advance the test's advantages; subsequently, this increments request among medical care experts and patients. Consolidating telemedicine and advanced wellbeing arrangements into POCT glucose testing is adding to the market's extension. As medical services frameworks utilize more associated checking approaches, this reconciliation further develops the general consideration continuum for people with diabetes and builds the productivity of diabetes management.

Point Of Care Glucose Testing Market Size Graph
Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Leave a Comment

FAQs

What is the current valuation of the Point Of Care Glucose Testing Market?

<p>The market valuation was 3.531 USD Billion in 2024.</p>

What is the projected market size for the Point Of Care Glucose Testing Market by 2035?

<p>The market is projected to reach 6.105 USD Billion by 2035.</p>

What is the expected CAGR for the Point Of Care Glucose Testing Market during the forecast period 2025 - 2035?

<p>The expected CAGR is 5.1% during the forecast period 2025 - 2035.</p>

Which companies are considered key players in the Point Of Care Glucose Testing Market?

<p>Key players include Roche Diagnostics, Abbott Laboratories, Bayer AG, Johnson & Johnson, Siemens Healthineers, Dexcom Inc., Ascensia Diabetes Care, Terumo Corporation, and Nova Biomedical.</p>

What are the main segments of the Point Of Care Glucose Testing Market?

<p>The main segments include Type, Application, and End User.</p>

How did the Blood-Glucose Meter segment perform in 2024?

<p>The Blood-Glucose Meter segment was valued at 2.468 USD Billion in 2024.</p>

What is the projected value of the Lancing Devices and Strips segment by 2035?

The Lancing Devices and Strips segment is projected to reach 1.823 USD Billion by 2035.

What is the market size for Type-1 Diabetes applications in 2024?

The market size for Type-1 Diabetes applications was 1.063 USD Billion in 2024.

What is the expected market size for Home Care Settings by 2035?

The market size for Home Care Settings is expected to reach 2.5 USD Billion by 2035.

How does the performance of the Others segment compare to other end users in 2024?

The Others segment was valued at 0.531 USD Billion in 2024, indicating a smaller share compared to Hospitals and Clinics and Home Care Settings.

Market Summary

As per Market Research Future analysis, the Point Of Care Glucose Testing Market was estimated at 3.531 USD Billion in 2024. The Point Of Care Glucose Testing industry is projected to grow from 3.712 USD Billion in 2025 to 6.105 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.1% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Point Of Care Glucose Testing Market is experiencing robust growth driven by technological advancements and increasing patient empowerment.

  • Technological advancements in glucose testing devices are enhancing accuracy and user-friendliness, thereby driving market growth. Increased patient empowerment is leading to a higher demand for home testing solutions, particularly in North America. The lancing devices and strips segment remains the largest, while blood-glucose meters are emerging as the fastest-growing segment in the market. Rising prevalence of diabetes and a shift towards home healthcare are key drivers propelling the market forward.

Market Size & Forecast

2024 Market Size 3.531 (USD Billion)
2035 Market Size 6.105 (USD Billion)
CAGR (2025 - 2035) 5.1%
Largest Regional Market Share in 2024 North America

Major Players

<a href="https://diagnostics.roche.com/global/en/products/product-category/lab-type/point-of-care-testing-poct/blood-glucose-testing.html">Roche Diagnostics</a> (CH), Abbott Laboratories (US), Bayer AG (DE), Johnson &amp; Johnson (US), Siemens Healthineers (DE), Dexcom Inc. (US), Ascensia Diabetes Care (DE), Terumo Corporation (JP), Nova Biomedical (US)

Market Trends

The Point Of Care Glucose Testing Market is currently experiencing a notable transformation, driven by advancements in technology and an increasing emphasis on patient-centered care within the wider point of care diagnostics market. The integration of digital health solutions, such as mobile applications and telemedicine, appears to enhance the accessibility and efficiency of glucose monitoring. This shift is likely to empower patients, enabling them to take charge of their health management. Furthermore, the growing prevalence of diabetes and related conditions is propelling demand for rapid and accurate testing methods, which are essential for timely clinical decisions. As healthcare systems evolve, the point-of-care glucose testing market is poised to expand, reflecting a broader trend towards decentralized healthcare delivery.

In addition, the market seems to be influenced by regulatory changes and the introduction of innovative devices that promise improved accuracy and user-friendliness. Manufacturers are increasingly focusing on developing portable and easy-to-use testing solutions, which could potentially enhance patient compliance and satisfaction. The emphasis on cost-effective healthcare solutions may also drive the adoption of point-of-care testing, as it allows for immediate results and reduces the need for extensive laboratory infrastructure. Overall, the point-of-care glucose testing market size is likely to witness sustained growth, shaped by technological advancements and evolving consumer preferences.

Technological Advancements

The Point Of Care Glucose Testing Market is witnessing rapid technological innovations, including advancements linked with the network point of care glucose testing market, where connected devices enable seamless data sharing and remote monitoring. These developments are contributing to the expanding network point-of-care glucose testing market ecosystem.

Increased Patient Empowerment

There is a growing trend towards empowering patients in their healthcare journey. The Point Of Care Glucose Testing Market reflects this shift, as more individuals seek tools that allow them to monitor their health independently, driving adoption within the connected network point of care glucose testing market size segment.

Regulatory Support and Innovation

Regulatory bodies are increasingly supporting the development of new testing solutions, which may facilitate the introduction of innovative products in the point-of-care glucose testing market. This support could encourage manufacturers to invest in research and development, leading to enhanced testing options.

Point Of Care Glucose Testing Market Market Drivers

Rising Prevalence of Diabetes

The increasing prevalence of diabetes worldwide is a primary driver for the Point Of Care Glucose Testing Market. According to recent estimates, the number of individuals diagnosed with diabetes is projected to reach approximately 700 million by 2045. This alarming trend necessitates efficient and accessible glucose monitoring solutions, thereby propelling the demand for point of care testing devices. As healthcare systems strive to manage this chronic condition effectively, the Point Of Care Glucose Testing Market is likely to experience substantial growth. The convenience and immediacy of these testing methods align with the needs of both patients and healthcare providers, fostering a shift towards more decentralized healthcare solutions.

Shift Towards Home Healthcare

The ongoing shift towards home healthcare is reshaping the Point Of Care Glucose Testing Market. Patients increasingly prefer to manage their health conditions from the comfort of their homes, leading to a rise in demand for at-home testing devices. This trend is supported by the growing awareness of diabetes management and the need for regular monitoring. The convenience of home testing not only empowers patients but also reduces the burden on healthcare facilities. As a result, the Point Of Care Glucose Testing Market is likely to see a significant uptick in sales of home-use glucose testing devices, reflecting a broader movement towards personalized healthcare solutions.

Supportive Regulatory Environment

A supportive regulatory environment is fostering innovation and growth within the Point Of Care Glucose Testing Market. Regulatory bodies are increasingly streamlining approval processes for new testing devices, encouraging manufacturers to bring innovative solutions to market. This regulatory support not only enhances the availability of advanced glucose testing technologies but also instills confidence among healthcare providers and patients. As regulations evolve to accommodate new technologies, the Point Of Care Glucose Testing Market is likely to benefit from increased product offerings and improved accessibility, ultimately enhancing patient care and management of diabetes.

Increased Focus on Preventive Healthcare

The heightened emphasis on preventive healthcare is driving growth in the Point Of Care Glucose Testing Market. Healthcare providers are increasingly recognizing the importance of early detection and management of diabetes to prevent complications. This shift is leading to greater investments in point of care testing solutions that facilitate timely interventions. As healthcare systems prioritize preventive measures, the demand for glucose testing devices that can be used in various settings, including clinics and pharmacies, is expected to rise. Consequently, the Point Of Care Glucose Testing Market is poised for expansion as stakeholders seek to enhance patient outcomes through proactive health management.

Technological Innovations in Testing Devices

Technological advancements in glucose testing devices are significantly influencing the Point Of Care Glucose Testing Market. Innovations such as continuous glucose monitoring systems and smartphone-integrated devices enhance user experience and accuracy. These advancements not only improve patient compliance but also facilitate real-time data sharing with healthcare professionals. The market is witnessing a surge in demand for devices that offer rapid results and user-friendly interfaces. As technology continues to evolve, the Point Of Care Glucose Testing Market is expected to expand, driven by the introduction of more sophisticated and efficient testing solutions that cater to the diverse needs of patients.

Market Segment Insights

By Type: Lancing Devices and Strips (Largest) vs. Blood-Glucose Meter (Fastest-Growing)

In the Point Of Care Glucose Testing Market, Lancing Devices and Strips hold a significant share, contributing to the overall point of care glucose testing market share due to steady demand for consumables. This segment benefits from the steady demand for consumables that work in tandem with glucose meters, providing a reliable means of blood sampling and testing. On the other hand, Blood-Glucose Meters are experiencing rapid growth, fueled by technological advancements and the increasing prevalence of diabetes worldwide. These devices have become more user-friendly and connected, leading to an uptick in adoption rates among patients and healthcare providers alike.

Lancing Devices and Strips (Dominant) vs. Blood-Glucose Meter (Emerging)

Lancing Devices and Strips serve as the backbone of the Point Of Care Glucose Testing Market, showcasing dominance through their essential role in the glucose testing process. These devices are characterized by their reliability and ease of use, providing users with the necessary tools to obtain blood samples for glucose monitoring. Conversely, Blood-Glucose Meters are emerging as a powerhouse segment due to the integration of smart technologies, such as mobile app connectivity and advanced data analytics. These innovations enhance patient engagement and provide healthcare professionals with valuable insights into glucose trends, thereby supporting better patient outcomes. This dynamic is crucial, as the market adapts to the growing demand for efficient and patient-centered diabetes management solutions.

By Application: Type-2 Diabetes (Largest) vs. Type-1 Diabetes (Fastest-Growing)

In the Point Of Care Glucose Testing Market, the distribution of application shares indicates that Type-2 Diabetes holds the largest market share, significantly leading over <a href="https://www.marketresearchfuture.com/reports/type-1-diabetes-treatment-market-8199">Type-1 Diabetes</a>. This dominance is attributed to the higher prevalence of Type-2 Diabetes globally, combined with increasing awareness and screening practices. Healthcare providers are focusing more on Type-2 due to its association with lifestyle factors, which necessitates regular monitoring for effective management and prevention strategies. Conversely, the Type-1 Diabetes segment is experiencing rapid growth, driven by advancements in testing technologies and increased investments in diabetes management. The rise in pediatric and adolescent diagnoses, along with a growing push for personalized healthcare, is further propelling this segment. Initiatives aimed at improving awareness and education around Type-1 Diabetes are also contributing to its accelerated market growth.

Application: Type-2 Diabetes (Dominant) vs. Type-1 Diabetes (Emerging)

The Type-2 Diabetes application in the Point Of Care Glucose Testing Market remains dominant, attracting significant usage due to its vast patient population. Patients often require frequent monitoring, creating consistent demand for testing products. The convenience and accessibility of point-of-care testing align well with the management needs of Type-2 Diabetes patients. On the other hand, the Type-1 Diabetes application, though currently smaller, is emerging rapidly. This segment is characterized by rising incidences among younger populations, requiring tailored testing solutions. The advancements in technology and a growing focus on continuous glucose monitoring systems are positioning Type-1 Diabetes as a crucial part of market growth, with innovative solutions catering to the unique needs of these patients.

By End User: Hospitals and Clinics (Largest) vs. Home Care Settings (Fastest-Growing)

In the Point Of Care Glucose Testing Market, the end-user segment is primarily dominated by Hospitals and Clinics, which account for a significant portion of market share. This preference can be attributed to the high volume of routine glucose monitoring required in clinical settings where patient management is critical. On the other hand, Home Care Settings are gaining traction, reflecting a shift towards patient-centric care and the growing demand for at-home monitoring solutions, especially with the rise of chronic diseases such as diabetes.

End User: Hospitals and Clinics (Dominant) vs. Home Care Settings (Emerging)

Within the Point Of Care Glucose Testing Market, Hospitals and Clinics emerge as the dominant end-users due to their extensive infrastructure and need for accurate and immediate glucose readings to make timely clinical decisions. These facilities typically have sophisticated testing modalities and skilled personnel optimizing their testing processes. On the contrary, Home Care Settings are classified as an emerging segment, driven by the increasing trend of self-monitoring among patients, coupled with advancements in accessible technology. As diabetes management continues to shift towards decentralized care, home testing devices are becoming essential for empowering patients, ultimately leading to improved outcomes.

Get more detailed insights about Point Of Care Glucose Testing Market Research Report 2035

Regional Insights

North America : Healthcare Innovation Leader

North America is the largest market for Point Of Care Glucose Testing Market, holding approximately 45% of the global share. The region's growth is driven by increasing diabetes prevalence, technological advancements, and supportive healthcare policies. Regulatory bodies like the FDA have streamlined approval processes for new devices, enhancing market dynamics. The demand for rapid testing solutions in both clinical and home settings is also on the rise, further propelling market growth. The United States leads the North American market, followed by Canada. Major players such as Abbott Laboratories, Johnson & Johnson, and Dexcom Inc. are heavily investing in R&D to innovate and expand their product lines. The competitive landscape is characterized by strategic partnerships and collaborations aimed at enhancing product offerings. The presence of advanced healthcare infrastructure and a high rate of diabetes awareness contribute to the region's market strength.

Europe : Emerging Market with Regulations

Europe is the second-largest market for Point Of Care Glucose Testing Market, accounting for around 30% of the global market share. The region's growth is driven by increasing diabetes cases, an aging population, and a shift towards decentralized healthcare. Regulatory frameworks, such as the EU Medical Device Regulation, are enhancing product safety and efficacy, thereby boosting consumer confidence and market demand. The emphasis on preventive healthcare is also a significant driver of growth in this sector. Germany, France, and the UK are the leading countries in this market, with Germany holding the largest share. Key players like Roche Diagnostics and Siemens Healthineers are focusing on innovation and expanding their product portfolios. The competitive landscape is marked by collaborations between manufacturers and healthcare providers to improve patient outcomes. The presence of a robust healthcare system and increasing investments in health technology further support market expansion.

Asia-Pacific : Rapidly Growing Market

Asia-Pacific is witnessing rapid growth in the Point Of Care Glucose Testing Market, holding approximately 20% of the global share. The region's growth is fueled by rising diabetes prevalence, increasing healthcare expenditure, and a growing focus on preventive healthcare. Countries like India and China are experiencing significant demand for glucose testing devices due to their large diabetic populations. Government initiatives aimed at improving healthcare access are also contributing to market expansion. China and India are the leading countries in this region, with a growing number of local and international players entering the market. Companies like Terumo Corporation and Nova Biomedical are expanding their presence through strategic partnerships and localized manufacturing. The competitive landscape is evolving, with an increasing emphasis on affordability and accessibility of testing solutions to cater to the diverse population needs.

Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region represents an emerging market for Point Of Care Glucose Testing Market, holding about 5% of the global share. The growth is driven by increasing diabetes prevalence, rising healthcare investments, and a growing awareness of diabetes management. However, challenges such as limited healthcare infrastructure and regulatory hurdles can impede market growth. Governments are increasingly recognizing the importance of diabetes care, leading to initiatives aimed at improving healthcare access and quality. South Africa and the UAE are the leading markets in this region, with a growing number of international players entering the landscape. Companies are focusing on establishing partnerships with local healthcare providers to enhance distribution and accessibility. The competitive environment is characterized by a mix of global and regional players, with an emphasis on affordable testing solutions to meet the needs of diverse populations.

Key Players and Competitive Insights

The Point Of Care Glucose Testing Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of diabetes globally. Key players such as Roche Diagnostics (Switzerland), Abbott Laboratories (US), and Dexcom Inc. (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Roche Diagnostics (Switzerland) focuses on innovation, particularly in developing integrated systems that combine glucose monitoring with data management solutions. Abbott Laboratories (US) emphasizes regional expansion, particularly in emerging markets, to capture a broader customer base. Meanwhile, Dexcom Inc. (US) is heavily investing in digital transformation, leveraging data analytics to improve patient outcomes and streamline operations. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and patient-centric solutions. In terms of business tactics, companies are localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with several players vying for market share, yet dominated by a few key companies that significantly influence trends and pricing. This competitive structure allows for a diverse range of products and services, catering to various consumer needs while fostering innovation through competition.
In August Abbott Laboratories (US) announced the launch of its latest continuous glucose monitoring system, which integrates seamlessly with mobile health applications. This strategic move not only enhances user experience but also positions Abbott as a leader in digital health solutions, potentially increasing its market share in the rapidly evolving landscape of diabetes management. The integration of mobile technology into glucose monitoring is likely to attract tech-savvy consumers, thereby expanding Abbott's customer base.
In September Roche Diagnostics (Switzerland) unveiled a new partnership with a leading telehealth provider to offer remote glucose monitoring services. This collaboration is strategically significant as it aligns with the growing trend of telemedicine, allowing Roche to tap into a broader market segment that prioritizes convenience and accessibility. By integrating their testing solutions with telehealth services, Roche is likely to enhance patient engagement and adherence to treatment protocols.
In October Dexcom Inc. (US) revealed advancements in its artificial intelligence algorithms designed to predict glucose fluctuations more accurately. This development is crucial as it not only improves the reliability of glucose monitoring but also positions Dexcom at the cutting edge of technology in diabetes management. The ability to provide predictive insights could significantly enhance patient outcomes, thereby solidifying Dexcom's competitive advantage in the market.
As of October current trends in the Point Of Care Glucose Testing Market indicate a strong shift towards digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to leverage complementary strengths and enhance their product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of developing robust, patient-centric solutions that not only meet regulatory standards but also address the evolving needs of consumers.

Key Companies in the Point Of Care Glucose Testing Market include

Industry Developments

  • Q2 2024: Abbott launches next-generation FreeStyle Libre 4 continuous glucose monitor in Europe Abbott announced the commercial launch of its FreeStyle Libre 4, a next-generation continuous glucose monitoring system, in select European markets. The device features enhanced accuracy and new connectivity features for point-of-care and home use.
  • Q2 2024: Dexcom Receives FDA Clearance for G7 Continuous Glucose Monitoring System for Hospital Point-of-Care Use Dexcom announced that the U.S. FDA has cleared its G7 continuous glucose monitoring system for use in hospital point-of-care settings, expanding its application beyond personal diabetes management.
  • Q1 2024: Roche launches Accu-Chek Instant Connect, a Bluetooth-enabled point-of-care glucose meter Roche introduced the Accu-Chek Instant Connect, a new Bluetooth-enabled glucose meter designed for rapid point-of-care testing and seamless integration with electronic health records in clinical settings.
  • Q2 2024: Ascensia Diabetes Care and Glooko Announce Partnership to Integrate Point-of-Care Glucose Data with Digital Diabetes Management Platform Ascensia Diabetes Care entered a partnership with Glooko to integrate data from its point-of-care glucose meters into Glooko’s digital diabetes management platform, enabling real-time data sharing between patients and healthcare providers.
  • Q3 2024: Trividia Health Receives CE Mark for TRUE METRIX AIR Professional Point-of-Care Glucose Meter Trividia Health announced it has received CE Mark approval for its TRUE METRIX AIR Professional, a new point-of-care glucose meter intended for use in hospitals and clinics across Europe.
  • Q1 2024: PTS Diagnostics Launches New Point-of-Care Glucose and HbA1c Analyzer in the U.S. PTS Diagnostics launched a new combined glucose and HbA1c analyzer for point-of-care use in the United States, targeting primary care clinics and community health centers.
  • Q2 2024: BioIntelliSense raises $45M Series B to expand wearable point-of-care glucose monitoring platform BioIntelliSense secured $45 million in Series B funding to accelerate the development and commercialization of its wearable point-of-care glucose monitoring platform for both hospital and home settings.
  • Q2 2024: Siemens Healthineers acquires GlySure, expanding point-of-care glucose monitoring portfolio Siemens Healthineers completed the acquisition of GlySure, a company specializing in continuous intravascular glucose monitoring, to strengthen its point-of-care diagnostics offerings.
  • Q3 2024: Nova Biomedical Opens New Manufacturing Facility for StatStrip Glucose Hospital Meters Nova Biomedical opened a new manufacturing facility dedicated to producing its StatStrip point-of-care glucose meters for hospital use, aiming to meet growing demand in North America and Europe.
  • Q2 2025: AgaMatrix Receives FDA 510(k) Clearance for WaveSense Jazz Wireless Pro Point-of-Care Glucose Meter AgaMatrix announced it has received FDA 510(k) clearance for its WaveSense Jazz Wireless Pro, a new point-of-care glucose meter designed for professional healthcare settings.
  • Q1 2025: EKF Diagnostics Launches STAT-Site WB Pro, a New Point-of-Care Glucose and Ketone Analyzer EKF Diagnostics launched the STAT-Site WB Pro, a new analyzer capable of measuring both glucose and ketone levels at the point of care, targeting emergency and critical care environments.
  • Q2 2025: Medtronic Announces Partnership with Microsoft to Develop AI-Driven Point-of-Care Glucose Monitoring Solutions Medtronic entered a partnership with Microsoft to co-develop artificial intelligence-powered solutions for point-of-care glucose monitoring, aiming to enhance clinical decision support and patient outcomes.

Future Outlook

Point Of Care Glucose Testing Market Future Outlook

The Point Of Care Glucose Testing Market is projected to grow at a 5.1% CAGR from 2025 to 2035, driven by technological advancements, increasing diabetes prevalence, and demand for rapid testing solutions.

New opportunities lie in:

  • <p>Development of portable glucose monitoring devices for home use. Integration of AI analytics for personalized diabetes management. Expansion of telehealth services for remote glucose monitoring.</p>

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

Market Segmentation

Point Of Care Glucose Testing Market Type Outlook

  • Lancing Devices and Strips
  • Blood-Glucose Meter

Point Of Care Glucose Testing Market End User Outlook

  • Hospitals and Clinics
  • Home Care Settings
  • Others

Point Of Care Glucose Testing Market Application Outlook

  • Type-1 Diabetes
  • Type-2 Diabetes

Report Scope

MARKET SIZE 2024 3.531(USD Billion)
MARKET SIZE 2025 3.712(USD Billion)
MARKET SIZE 2035 6.105(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.1% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Roche Diagnostics (CH), Abbott Laboratories (US), Bayer AG (DE), Johnson & Johnson (US), Siemens Healthineers (DE), Dexcom Inc. (US), Ascensia Diabetes Care (DE), Terumo Corporation (JP), Nova Biomedical (US)
Segments Covered Product Type, Applications, End Users, Region
Key Market Opportunities Integration of advanced digital health technologies enhances patient engagement in the Point Of Care Glucose Testing Market.
Key Market Dynamics Technological advancements and regulatory changes drive innovation and competition in the Point Of Care Glucose Testing Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Point Of Care Glucose Testing Market?

<p>The market valuation was 3.531 USD Billion in 2024.</p>

What is the projected market size for the Point Of Care Glucose Testing Market by 2035?

<p>The market is projected to reach 6.105 USD Billion by 2035.</p>

What is the expected CAGR for the Point Of Care Glucose Testing Market during the forecast period 2025 - 2035?

<p>The expected CAGR is 5.1% during the forecast period 2025 - 2035.</p>

Which companies are considered key players in the Point Of Care Glucose Testing Market?

<p>Key players include Roche Diagnostics, Abbott Laboratories, Bayer AG, Johnson & Johnson, Siemens Healthineers, Dexcom Inc., Ascensia Diabetes Care, Terumo Corporation, and Nova Biomedical.</p>

What are the main segments of the Point Of Care Glucose Testing Market?

<p>The main segments include Type, Application, and End User.</p>

How did the Blood-Glucose Meter segment perform in 2024?

<p>The Blood-Glucose Meter segment was valued at 2.468 USD Billion in 2024.</p>

What is the projected value of the Lancing Devices and Strips segment by 2035?

The Lancing Devices and Strips segment is projected to reach 1.823 USD Billion by 2035.

What is the market size for Type-1 Diabetes applications in 2024?

The market size for Type-1 Diabetes applications was 1.063 USD Billion in 2024.

What is the expected market size for Home Care Settings by 2035?

The market size for Home Care Settings is expected to reach 2.5 USD Billion by 2035.

How does the performance of the Others segment compare to other end users in 2024?

The Others segment was valued at 0.531 USD Billion in 2024, indicating a smaller share compared to Hospitals and Clinics and Home Care Settings.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Type (USD Billion)
    2. | | 4.1.1 Lancing Devices and Strips
    3. | | 4.1.2 Blood-Glucose Meter
    4. | 4.2 Healthcare, BY Application (USD Billion)
    5. | | 4.2.1 Type-1 Diabetes
    6. | | 4.2.2 Type-2 Diabetes
    7. | 4.3 Healthcare, BY End User (USD Billion)
    8. | | 4.3.1 Hospitals and Clinics
    9. | | 4.3.2 Home Care Settings
    10. | | 4.3.3 Others
    11. | 4.4 Healthcare, BY Region (USD Billion)
    12. | | 4.4.1 North America
    13. | | | 4.4.1.1 US
    14. | | | 4.4.1.2 Canada
    15. | | 4.4.2 Europe
    16. | | | 4.4.2.1 Germany
    17. | | | 4.4.2.2 UK
    18. | | | 4.4.2.3 France
    19. | | | 4.4.2.4 Russia
    20. | | | 4.4.2.5 Italy
    21. | | | 4.4.2.6 Spain
    22. | | | 4.4.2.7 Rest of Europe
    23. | | 4.4.3 APAC
    24. | | | 4.4.3.1 China
    25. | | | 4.4.3.2 India
    26. | | | 4.4.3.3 Japan
    27. | | | 4.4.3.4 South Korea
    28. | | | 4.4.3.5 Malaysia
    29. | | | 4.4.3.6 Thailand
    30. | | | 4.4.3.7 Indonesia
    31. | | | 4.4.3.8 Rest of APAC
    32. | | 4.4.4 South America
    33. | | | 4.4.4.1 Brazil
    34. | | | 4.4.4.2 Mexico
    35. | | | 4.4.4.3 Argentina
    36. | | | 4.4.4.4 Rest of South America
    37. | | 4.4.5 MEA
    38. | | | 4.4.5.1 GCC Countries
    39. | | | 4.4.5.2 South Africa
    40. | | | 4.4.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Roche Diagnostics (CH)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Abbott Laboratories (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Bayer AG (DE)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Johnson & Johnson (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Siemens Healthineers (DE)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Dexcom Inc. (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Ascensia Diabetes Care (DE)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Terumo Corporation (JP)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Nova Biomedical (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY TYPE
    4. | 6.4 US MARKET ANALYSIS BY APPLICATION
    5. | 6.5 US MARKET ANALYSIS BY END USER
    6. | 6.6 CANADA MARKET ANALYSIS BY TYPE
    7. | 6.7 CANADA MARKET ANALYSIS BY APPLICATION
    8. | 6.8 CANADA MARKET ANALYSIS BY END USER
    9. | 6.9 EUROPE MARKET ANALYSIS
    10. | 6.10 GERMANY MARKET ANALYSIS BY TYPE
    11. | 6.11 GERMANY MARKET ANALYSIS BY APPLICATION
    12. | 6.12 GERMANY MARKET ANALYSIS BY END USER
    13. | 6.13 UK MARKET ANALYSIS BY TYPE
    14. | 6.14 UK MARKET ANALYSIS BY APPLICATION
    15. | 6.15 UK MARKET ANALYSIS BY END USER
    16. | 6.16 FRANCE MARKET ANALYSIS BY TYPE
    17. | 6.17 FRANCE MARKET ANALYSIS BY APPLICATION
    18. | 6.18 FRANCE MARKET ANALYSIS BY END USER
    19. | 6.19 RUSSIA MARKET ANALYSIS BY TYPE
    20. | 6.20 RUSSIA MARKET ANALYSIS BY APPLICATION
    21. | 6.21 RUSSIA MARKET ANALYSIS BY END USER
    22. | 6.22 ITALY MARKET ANALYSIS BY TYPE
    23. | 6.23 ITALY MARKET ANALYSIS BY APPLICATION
    24. | 6.24 ITALY MARKET ANALYSIS BY END USER
    25. | 6.25 SPAIN MARKET ANALYSIS BY TYPE
    26. | 6.26 SPAIN MARKET ANALYSIS BY APPLICATION
    27. | 6.27 SPAIN MARKET ANALYSIS BY END USER
    28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
    29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY END USER
    31. | 6.31 APAC MARKET ANALYSIS
    32. | 6.32 CHINA MARKET ANALYSIS BY TYPE
    33. | 6.33 CHINA MARKET ANALYSIS BY APPLICATION
    34. | 6.34 CHINA MARKET ANALYSIS BY END USER
    35. | 6.35 INDIA MARKET ANALYSIS BY TYPE
    36. | 6.36 INDIA MARKET ANALYSIS BY APPLICATION
    37. | 6.37 INDIA MARKET ANALYSIS BY END USER
    38. | 6.38 JAPAN MARKET ANALYSIS BY TYPE
    39. | 6.39 JAPAN MARKET ANALYSIS BY APPLICATION
    40. | 6.40 JAPAN MARKET ANALYSIS BY END USER
    41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
    42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY END USER
    44. | 6.44 MALAYSIA MARKET ANALYSIS BY TYPE
    45. | 6.45 MALAYSIA MARKET ANALYSIS BY APPLICATION
    46. | 6.46 MALAYSIA MARKET ANALYSIS BY END USER
    47. | 6.47 THAILAND MARKET ANALYSIS BY TYPE
    48. | 6.48 THAILAND MARKET ANALYSIS BY APPLICATION
    49. | 6.49 THAILAND MARKET ANALYSIS BY END USER
    50. | 6.50 INDONESIA MARKET ANALYSIS BY TYPE
    51. | 6.51 INDONESIA MARKET ANALYSIS BY APPLICATION
    52. | 6.52 INDONESIA MARKET ANALYSIS BY END USER
    53. | 6.53 REST OF APAC MARKET ANALYSIS BY TYPE
    54. | 6.54 REST OF APAC MARKET ANALYSIS BY APPLICATION
    55. | 6.55 REST OF APAC MARKET ANALYSIS BY END USER
    56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. | 6.57 BRAZIL MARKET ANALYSIS BY TYPE
    58. | 6.58 BRAZIL MARKET ANALYSIS BY APPLICATION
    59. | 6.59 BRAZIL MARKET ANALYSIS BY END USER
    60. | 6.60 MEXICO MARKET ANALYSIS BY TYPE
    61. | 6.61 MEXICO MARKET ANALYSIS BY APPLICATION
    62. | 6.62 MEXICO MARKET ANALYSIS BY END USER
    63. | 6.63 ARGENTINA MARKET ANALYSIS BY TYPE
    64. | 6.64 ARGENTINA MARKET ANALYSIS BY APPLICATION
    65. | 6.65 ARGENTINA MARKET ANALYSIS BY END USER
    66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
    67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    69. | 6.69 MEA MARKET ANALYSIS
    70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
    71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER
    73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
    74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER
    76. | 6.76 REST OF MEA MARKET ANALYSIS BY TYPE
    77. | 6.77 REST OF MEA MARKET ANALYSIS BY APPLICATION
    78. | 6.78 REST OF MEA MARKET ANALYSIS BY END USER
    79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. | 6.80 RESEARCH PROCESS OF MRFR
    81. | 6.81 DRO ANALYSIS OF HEALTHCARE
    82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. | 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
    86. | 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
    87. | 6.87 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    88. | 6.88 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    89. | 6.89 HEALTHCARE, BY END USER, 2024 (% SHARE)
    90. | 6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY END USER, 2025-2035 (USD Billion)
    7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    8. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
    9. | | 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
    10. | | 7.3.3 BY END USER, 2025-2035 (USD Billion)
    11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    12. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
    13. | | 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
    14. | | 7.4.3 BY END USER, 2025-2035 (USD Billion)
    15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    16. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
    17. | | 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
    18. | | 7.5.3 BY END USER, 2025-2035 (USD Billion)
    19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    20. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
    21. | | 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
    22. | | 7.6.3 BY END USER, 2025-2035 (USD Billion)
    23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
    25. | | 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
    26. | | 7.7.3 BY END USER, 2025-2035 (USD Billion)
    27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    28. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
    29. | | 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
    30. | | 7.8.3 BY END USER, 2025-2035 (USD Billion)
    31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    32. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
    33. | | 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
    34. | | 7.9.3 BY END USER, 2025-2035 (USD Billion)
    35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    36. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
    37. | | 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
    38. | | 7.10.3 BY END USER, 2025-2035 (USD Billion)
    39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    40. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
    41. | | 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
    42. | | 7.11.3 BY END USER, 2025-2035 (USD Billion)
    43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
    45. | | 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
    46. | | 7.12.3 BY END USER, 2025-2035 (USD Billion)
    47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    48. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
    49. | | 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
    50. | | 7.13.3 BY END USER, 2025-2035 (USD Billion)
    51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    52. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
    53. | | 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
    54. | | 7.14.3 BY END USER, 2025-2035 (USD Billion)
    55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    56. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
    57. | | 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
    58. | | 7.15.3 BY END USER, 2025-2035 (USD Billion)
    59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    60. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
    61. | | 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
    62. | | 7.16.3 BY END USER, 2025-2035 (USD Billion)
    63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
    65. | | 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
    66. | | 7.17.3 BY END USER, 2025-2035 (USD Billion)
    67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    68. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
    69. | | 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
    70. | | 7.18.3 BY END USER, 2025-2035 (USD Billion)
    71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    72. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
    73. | | 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
    74. | | 7.19.3 BY END USER, 2025-2035 (USD Billion)
    75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    76. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
    77. | | 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
    78. | | 7.20.3 BY END USER, 2025-2035 (USD Billion)
    79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    80. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
    81. | | 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
    82. | | 7.21.3 BY END USER, 2025-2035 (USD Billion)
    83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
    85. | | 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
    86. | | 7.22.3 BY END USER, 2025-2035 (USD Billion)
    87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    88. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
    89. | | 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
    90. | | 7.23.3 BY END USER, 2025-2035 (USD Billion)
    91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    92. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
    93. | | 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
    94. | | 7.24.3 BY END USER, 2025-2035 (USD Billion)
    95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    96. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
    97. | | 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
    98. | | 7.25.3 BY END USER, 2025-2035 (USD Billion)
    99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    100. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
    101. | | 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
    102. | | 7.26.3 BY END USER, 2025-2035 (USD Billion)
    103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
    105. | | 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
    106. | | 7.27.3 BY END USER, 2025-2035 (USD Billion)
    107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    108. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
    109. | | 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
    110. | | 7.28.3 BY END USER, 2025-2035 (USD Billion)
    111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    112. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
    113. | | 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
    114. | | 7.29.3 BY END USER, 2025-2035 (USD Billion)
    115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    116. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
    117. | | 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
    118. | | 7.30.3 BY END USER, 2025-2035 (USD Billion)
    119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    120. | | 7.31.1
    121. | 7.32 ACQUISITION/PARTNERSHIP
    122. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Lancing Devices and Strips
  • Blood-Glucose Meter

Healthcare By Application (USD Billion, 2025-2035)

  • Type-1 Diabetes
  • Type-2 Diabetes

Healthcare By End User (USD Billion, 2025-2035)

  • Hospitals and Clinics
  • Home Care Settings
  • Others
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Customer Strories

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions
%>